Abstract
Recently, the European Society of Endocrinology (ESE) published new guidelines on the management of adrenal incidentalomas. At the same time Lopez and coworkers published on the Annals of Internal Medicine an important study showing that even patients with non-functioning adrenal tumors have an increased risk of incident diabetes. In consideration of previous data and of the results of the study of Lopez and coworkers, some points emerge from the ESE Guidelines that deserve attention. Firstly, it must be observed that the term “autonomous cortisol secretion,” introduced by the ESE Panel in the place of the commonly used “subclinical hypercortisolism,” seems questionable, since the guidelines do not suggest determining the adrenocorticotroph hormone levels that could give the certain proof of a truly autonomous cortisol secretion. Secondly, the ESE Guidelines suggest against repeated hormonal workup in AI patients with a normal hormonal secretion at initial evaluation, but also in those with a “possible autonomous cortisol secretion,” if in the absence of comorbidities potentially related to hypercortisolism. Thirdly, the ESE Guidelines suggest against further imaging during follow-up in patients with an adrenal mass below 4 cm in size with clear benign features on imaging studies. Considering the available literature data that are briefly summarized in this comment, we believe that no sufficient evidence is available to date for giving sharp-cutting recommendations about the uselessness of a biochemical and morphological follow-up in AI patients, even in those with initially benign and not hypersecreting adrenal adenomas. However, if a recommendation has to be given on the basis of the present evidences, we should suggest to biochemically and morphologically follow-up AI patients for at least 5 years.
References
Chiodini I, Albani A, Ambrogio AG, Campo M, De Martino MC, Marcelli G et al (2016) Six controversial issues on subclinical Cushing’s syndrome. Endocrine epub ahead of print, doi: 10.1007/s12020-016-1017-3
Chiodini I, Morelli V (2016) Subclinical hypercortisolism: how to deal with it. Front Horm Res 46:28–38
Masserini B, Morelli V, Palmieri S, Eller-Vainicher C, Zhukouskaya V, Cairoli E et al (2015) Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. J Endocrinol Invest 38:623–628
Tuna MM, Imga NN, Doğan BA, Yılmaz FM, Topçuoğlu C, Akbaba G et al (2014) Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. J Endocrinol Invest 37:765–768
Shen J, Sun M, Zhou B, Yan J (2014) Nonconformity in the clinical practice guidelines for subclinical Cushing’s syndrome: which guidelines are trustworthy? Eur J Endocrinol 171:421–431
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A et al (2016) Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 175:G1–G34
Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (2016) “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med epub ahead of print. doi:10.7326/M16-0547
Barzon L et al (1999) Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84:520–526
Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S et al (2010) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834
Bernini GP et al (2005) Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer 92:1104–1109
Anagnostis P et al (2010) Long term follow-up of patients with adrenal incidentalomas—a single center experience and review of the literature. Exp Clin Endocrinol Diabetes 118:610–616
Vassilatou E et al (2009) Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol 70:674–679
Di Dalmazi G et al (2014) Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2:396–405
Fagour A et al (2009) Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. Eur J Endocrinol 160:257–264
Giordano R et al (2010) Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol 162:779–785
Muth A et al (2011) Adrenal study group of Western Sweden. Cohort study of patients with adrenal lesions discovered incidentally. Br J Surg 98:1383–1391
Cho YY et al (2013) Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med 28:557–564
Comlekci A et al (2010) Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocr 37:40–46
Yener S et al (2010) Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 33:32–36
Libè R et al (2002) Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 147:489–494
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J (2014) Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 99:4462–4467
Morelli V, Eller-Vainicher C, Palmieri S, Cairoli E, Salcuni AS, Scillitani A et al (2016) Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas. J Clin Endocrinol Metab 101:2768–2775
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study informed consent is not required.
Rights and permissions
About this article
Cite this article
Morelli, V., Scillitani, A., Arosio, M. et al. Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe?. J Endocrinol Invest 40, 331–333 (2017). https://doi.org/10.1007/s40618-016-0558-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-016-0558-x